Arthritis drug Actemra still not a solution to Covid-19

Tocilizumab an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis. [Photo: Courtesy]

The long search for a possible cure for Covid-19 is yet to be over. EMPACTA (Evaluating Minority Patients with Actemra) trial which was ongoing in the country has revealed that Actemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with Covid-19 associated pneumonia.

EMPACTA is the first global clinical trial to show efficacy with Actemra in Covid-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patients.